Exocure Therapeutics

Company Overview

Snapshot

Founded in September 2025 by Reem Miari and Mizied Falah Mizied Falah, Exocure Therapeutics operates with 1–10 employees. The company is currently in the R&D product stage, focusing on developing exosome-based cancer therapeutics.

Business overview

Exocure Therapeutics is a Health Tech & Life Sciences company specializing in Pharma & Medical Biotechnology, with a focus on Drugs Discovery & Development. The company develops exosome-based cancer therapeutics designed to selectively target tumor pathways while minimizing harm to healthy cells. Its lead program targets breast and pancreatic cancers, offering an IV-administered therapy for standalone use or in combination with existing oncology treatments. The technology leverages exosomes sourced from naturally cancer-resistant tissue, with plans for scalable manufacturing using human cell lines and future potential to engineer exosomes for targeted delivery of therapeutic cargo.

Company Intelligence Q&A

When was Exocure Therapeutics founded?

Exocure Therapeutics was founded in September 2025.

Who are the founders of Exocure Therapeutics?

The co-founders of Exocure Therapeutics are Reem Miari, who serves as CEO, and Mizied Falah Mizied Falah, who is the CSO.

What is Exocure Therapeutics' primary focus?

Exocure Therapeutics focuses on developing exosome-based cancer therapeutics, with its lead program targeting breast and pancreatic cancers.

What is the current product stage of Exocure Therapeutics?

Exocure Therapeutics is currently in the R&D product stage, developing its exosome-based cancer therapies.

What is the core technology behind Exocure Therapeutics' therapies?

Exocure Therapeutics' core technology involves using exosomes sourced from naturally cancer-resistant tissue, with future plans to engineer these exosomes to carry therapeutic cargo for targeted delivery.